Literature DB >> 35694692

Synthesis and anticancer activity of two highly water-soluble and ionic Pt(iv) complexes as prodrugs for Pt(ii) anticancer drugs.

Anli Gao1, Yaxi Wu2,3, Juan Yu1, Hongyu Gong2, Jing Jiang1, Caihong Yang2, Weiping Liu1, Chen Qing2.   

Abstract

Two new Pt(iv) complexes featuring mesylate as the outer sphere anion, cis,trans,cis-[PtCl2(OH2)2(NH3)2](CH3SO3)2 (SPt-1) and cis,trans,cis-[PtCl2(OH2)2(1R,2R-DACH)](CH3SO3)2 (SPt-2), were synthesized and characterized by elemental analysis, 1H and 13C NMR, IR, and ESI-MS. Both complexes have excellent water-solubility, high molar conductivity and good water stability. They exhibit an irreversible two-electron reduction event with the peak potentials (E p) for the processes being -0.40 V for SPt-1 and -0.52 V for SPt-2. The biological tests reveal that SPt-2 possesses high in vitro anticancer activity against three human cancer cell lines (HCT-116, A549 and MKN-1) and its overall anticancer activity is slightly greater than that of oxaliplatin, whereas SPt-1 is less active than cisplatin. Moreover, the antitumor efficacy of SPt-2 on human colon carcinoma HCT-116 xenografts in nude mice is also greater than that of oxaliplatin, suggesting that SPt-2 deserves further evaluation as a prodrug for oxaliplatin. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2022        PMID: 35694692      PMCID: PMC9132197          DOI: 10.1039/d2md00004k

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  22 in total

1.  Advances in platinum chemotherapeutics.

Authors:  Benjamin W Harper; Anwen M Krause-Heuer; Maxine P Grant; Madhura Manohar; K Benjamin Garbutcheon-Singh; Janice R Aldrich-Wright
Journal:  Chemistry       Date:  2010-06-25       Impact factor: 5.236

Review 2.  Metal-based anticancer chemotherapeutic agents.

Authors:  Nafees Muhammad; Zijian Guo
Journal:  Curr Opin Chem Biol       Date:  2014-03-05       Impact factor: 8.822

3.  Polysilsesquioxane nanoparticles for targeted platin-based cancer chemotherapy by triggered release.

Authors:  Joseph Della Rocca; Rachel C Huxford; Erica Comstock-Duggan; Wenbin Lin
Journal:  Angew Chem Int Ed Engl       Date:  2011-09-14       Impact factor: 15.336

4.  Studies of the binding of a series of platinum(IV) complexes to plasma proteins.

Authors:  Rachael C Dolman; Glen B Deacon; Trevor W Hambley
Journal:  J Inorg Biochem       Date:  2002-02       Impact factor: 4.155

5.  Cis,cis,trans-[PtIVCl2(NH3)2(perillato)2], a dual-action prodrug with excellent cytotoxic and antimetastatic activity.

Authors:  Mauro Ravera; Elisabetta Gabano; Ilaria Zanellato; Beatrice Rangone; Elena Perin; Beatrice Ferrari; Maria Grazia Bottone; Domenico Osella
Journal:  Dalton Trans       Date:  2021-02-17       Impact factor: 4.390

6.  Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer.

Authors:  C N Sternberg; P Whelan; J Hetherington; B Paluchowska; P H Th J Slee; K Vekemans; P Van Erps; C Theodore; O Koriakine; T Oliver; D Lebwohl; M Debois; A Zurlo; L Collette
Journal:  Oncology       Date:  2005-02-28       Impact factor: 2.935

Review 7.  Platinum complexes as anticancer agents.

Authors:  Irena Kostova
Journal:  Recent Pat Anticancer Drug Discov       Date:  2006-01       Impact factor: 4.169

Review 8.  The resurgence of platinum-based cancer chemotherapy.

Authors:  Lloyd Kelland
Journal:  Nat Rev Cancer       Date:  2007-07-12       Impact factor: 60.716

9.  The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo.

Authors:  Pavel Bouchal; Jiri Jarkovsky; Kristyna Hrazdilova; Monika Dvorakova; Iva Struharova; Lenka Hernychova; Jiri Damborsky; Petr Sova; Borivoj Vojtesek
Journal:  Proteome Sci       Date:  2011-10-31       Impact factor: 2.480

10.  A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.

Authors:  Beatrice Ferrari; Elisa Roda; Erica Cecilia Priori; Fabrizio De Luca; Angelica Facoetti; Mauro Ravera; Federico Brandalise; Carlo Alessandro Locatelli; Paola Rossi; Maria Grazia Bottone
Journal:  Front Neurosci       Date:  2021-03-22       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.